Phase 1/2 trial of GCLAM with dose-escalated mitoxantrone for newly diagnosed AML or other high-grade myeloid neoplasms.
Halpern AB, Othus M, Huebner EM, Scott BL, Becker PS, Percival MM, Hendrie PC, Gardner KM, Chen TL, Buckley SA, Orlowski KF, Anwar A, Appelbaum FR, Erba HP, Estey EH, Walter RB.
Halpern AB, et al.
Leukemia. 2018 Nov;32(11):2352-2362. doi: 10.1038/s41375-018-0135-8. Epub 2018 Apr 17.
Leukemia. 2018.
PMID: 29720734
Free PMC article.
Clinical Trial.